Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Equity Ratio (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Equity Ratio for 8 consecutive years, with 0.38 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio rose 12.58% year-over-year to 0.38, compared with a TTM value of 0.38 through Sep 2025, up 12.58%, and an annual FY2024 reading of 0.15, down 56.41% over the prior year.
  • Equity Ratio was 0.38 for Q3 2025 at X4 Pharmaceuticals, up from 0.04 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.65 in Q1 2021 and bottomed at 0.01 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.39, with a median of 0.39 recorded in 2023.
  • The sharpest move saw Equity Ratio crashed 97.78% in 2024, then skyrocketed 1810.93% in 2025.
  • Year by year, Equity Ratio stood at 0.55 in 2021, then dropped by 13.42% to 0.48 in 2022, then fell by 27.09% to 0.35 in 2023, then tumbled by 56.41% to 0.15 in 2024, then skyrocketed by 149.1% to 0.38 in 2025.
  • Business Quant data shows Equity Ratio for XFOR at 0.38 in Q3 2025, 0.04 in Q2 2025, and 0.18 in Q1 2025.